Park, J. J., Howard, L. E., Fragkogianni, S., George, D. J., & Armstrong, A. J. (2026). Outcomes for patients with SPOP mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI). Clinical Genitourinary Cancer, 102502–102502. https://doi.org/10.1016/j.clgc.2026.102502

Park, Joseph J., Lauren E. Howard, Stamatina Fragkogianni, Daniel J. George, and Andrew J. Armstrong. “Outcomes for patients with SPOP mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).” Clinical Genitourinary Cancer, January 2026, 102502–102502. https://doi.org/10.1016/j.clgc.2026.102502.

Park JJ, Howard LE, Fragkogianni S, George DJ, Armstrong AJ. Outcomes for patients with SPOP mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI). Clinical Genitourinary Cancer. 2026 Jan;102502–102502.

Park, Joseph J., et al. “Outcomes for patients with SPOP mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).” Clinical Genitourinary Cancer, Elsevier BV, Jan. 2026, pp. 102502–102502. Crossref, doi:10.1016/j.clgc.2026.102502.

Park JJ, Howard LE, Fragkogianni S, George DJ, Armstrong AJ. Outcomes for patients with SPOP mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI). Clinical Genitourinary Cancer. Elsevier BV; 2026 Jan;102502–102502.